| Section | Provisional content |
|---|---|
| Retrieval limitation note | No citable contexts were retrievable in this run, so all publication-specific statements below are seed-anchored and require full-text manual verification against the cited PubMed records before curation use. |
| Executive judgment | **Partially supported (provisional).** The seed evidence is consistent with biallelic or otherwise damaging **SYCE1** variants causing meiotic failure via synaptonemal-complex dysfunction, but confidence is limited because the underlying papers could not be retrieved or verified in this session. |
| Evidence matrix (seed PMIDs + PubMed URLs) | **PMID:25062452** — https://pubmed.ncbi.nlm.nih.gov/25062452/ — familial human POI/primary amenorrhea with homozygous nonsense SYCE1 variant; **PMID:32402064** — https://pubmed.ncbi.nlm.nih.gov/32402064/ — model evidence for absent SYCE1/reduced transcript and synapsis-related infertility mechanism; **PMID:34718620** — https://pubmed.ncbi.nlm.nih.gov/34718620/ — SYCE1 variants reported to disrupt interaction with SYCP1 and/or C14ORF39/SIX6OS1, affecting SC assembly; **PMID:35718780** — https://pubmed.ncbi.nlm.nih.gov/35718780/ — human NOA cases with SYCE1 CNVs and pachytene-stage arrest on H&E/IF. |
| Clinical spectrum: 46,XX | Seed evidence supports **primary ovarian insufficiency / primary amenorrhea** in 46,XX individuals; detailed endocrine values, ovarian imaging, and follicle depletion data were not retrievable here and need full-text confirmation. |
| Clinical spectrum: 46,XY | Seed evidence supports **non-obstructive azoospermia** with **pachytene-stage spermatogenic arrest** on histology/immunofluorescence in 46,XY individuals; semen details, hormone values, and biopsy-marker specifics remain unverified in this run. |
| Variant & inheritance summary | Provisional inheritance model: **autosomal recessive / biallelic**. Seed evidence mentions a **homozygous nonsense variant c.613C>T**, additional damaging variants affecting SYCE1 interactions, and **SYCE1 CNVs**; exact zygosity/phasing, family counts, and classification details require full-text verification. |
| Mechanistic causal chain | Provisional chain: **biallelic SYCE1 loss/damaging variant -> reduced or absent SYCE1 -> disrupted interaction with SYCP1 and/or C14ORF39/SIX6OS1 -> synaptonemal-complex central element assembly failure -> homologous chromosome synapsis failure -> pachytene arrest/checkpoint activation -> germ-cell depletion -> 46,XX POI/primary amenorrhea or 46,XY NOA/spermatogenic arrest**. Intermediate links are supported mainly by model/in vitro seed evidence and need direct verification. |
| Diagnostics / management implications | Provisional practice implications: include **SYCE1** on infertility/POI/NOA testing panels with **CNV detection**; in 46,XY consider semen analysis, endocrine evaluation, and biopsy when indicated; in 46,XX assess ovarian reserve and POI biochemistry. Management is expected to follow standard POI/NOA care pathways, including hormone replacement for POI as indicated, fertility counseling, donor-oocyte discussion, and cautious consideration of micro-TESE/ICSI in NOA. |
| Ontology suggestions (HPO/GO/CL/treatments) | **HPO:** Primary ovarian insufficiency; Primary amenorrhea; Female infertility; Azoospermia; Non-obstructive azoospermia; Spermatogenic arrest; Hypergonadotropic hypogonadism. **GO:** Meiotic cell cycle; Homologous chromosome pairing; Synaptonemal complex assembly; Meiotic recombination; Germ cell apoptotic process. **CL:** Primary oocyte; Spermatocyte; Pachytene spermatocyte; Germ cell. **Treatment/action terms:** Genetic testing; Genetic counseling; Hormone replacement therapy; Fertility preservation; Oocyte cryopreservation; Micro-TESE; ICSI; PGT-M. |
| Knowledge gaps | Major gaps reflect the retrieval block: no full-text verification, no figure/table access, no confirmed endocrine or histologic detail, uncertain CNV zygosity/phasing, and limited ability to separate direct human evidence from mouse or in vitro inference. No 2023–2024 studies could be identified or prioritized in this run. |
| Curator leads | After manual verification, consider annotating: (1) **meiotic synaptonemal-complex central element assembly defect** as the core mechanism; (2) dual-sex phenotype of **46,XX POI/primary amenorrhea** and **46,XY NOA/pachytene arrest**; (3) support for **loss-of-function and CNV** mechanisms; (4) partner-interaction mechanism involving **SYCP1** and **C14ORF39/SIX6OS1**. |
| Verification status | **Full-text verification is required** for all seed-paper claims because no citable contexts were retrievable in this session. |


*Table: This table summarizes a concise, curator-oriented provisional report for SYCE1-related gametogenic failure using only the seed PMIDs and PubMed links. It is useful because it organizes the mechanistic hypothesis, phenotype spectrum, variant classes, and verification needs in one place while clearly documenting the literature retrieval block.*